FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average b	ourden
houre par rachanca	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * GERSON IRWIN		2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]					_x_	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X_ Director10% Owner							
(Last) (First) (Middle) C/O ENZO BIOCHEM, 527 MADISON AVENUE (Street) NEW YORK, NY 10022				Date of Earliest Transaction (Month/Day/Year) 01/22/2009 4. If Amendment, Date Original Filed(Month/Day/Year)						Officer (give	title below)	Other	(specify below)		
			4						_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City)		(State)	(Zip)			Tal	ole I -	- Non-Deriv	ative Securities	Acquired,	Disposed	of, or Bene	ficially Owned		
1.Title of Sec (Instr. 3)	curity		2. Transaction Date (Month/Day/Year)	2A. Deer Executio any (Month/I	n Dat	e, if Co (Ir (ear)	ode istr. 8	(A) (Ir	Securities Acqu o) or Disposed o astr. 3, 4 and 5)	f (D) Owner Trans (Instr		ecurities Be ng Reported	O FO D OI (I	wnership of Be irect (D) (Ir Indirect)	Nature Indirect eneficial wnership nstr. 4)
							Code	e V Ai	mount (D)	Price			(1	nstr. 4)	
Reminder: Re	enort on a ser	narate line for each o	liass of securifies be	eneticialiv	owne	a arreci									
		parate line for each o	Table II -	Derivativ	e Sec	urities A	Acqui	Persons in this for a curren ired, Dispos	who respond orm are not re tly valid OMB sed of, or Benef evertible securi	quired to r control nu icially Own	espond (Imber.	unless the	form display	'S	74 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Table II - 3A. Deemed Execution Date, if	Derivativ (e.g., puts 4. Transact Code	se Section of S	urities A	Acquiants, or er attive s l (A) sed	Persons in this for a curren ired, Disposoptions, con 6. Date Exe Expiration 1 (Month/Day	orm are not re tly valid OMB sed of, or Benef exertible securion reisable and Date	quired to r control nu icially Own	espond umber. ed Amount	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indire Beneficia
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	Derivativ (e.g., puts 4. Transact Code	se Section of S	urities As, warra . Number f Deriva securities Acquired or Dispose f (D) Instr. 3, nd 5)	Acquints, of er attive s s l (A) ssed 4,	Persons in this for a curren ired, Disposoptions, con 6. Date Exe Expiration 1 (Month/Day	orm are not rettly valid OMB sed of, or Benef evertible securit reisable and Date y/Year) Expiration	quired to r control nu icially Own icially Own icially Own icially Own 7. Title and of Underlyi Securities	espond umber. ed Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indire Beneficia Ownersh

Reporting Owners

B 41 0 W 4	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
GERSON IRWIN C/O ENZO BIOCHEM 527 MADISON AVENUE NEW YORK, NY 10022	X				

Signatures

/s/ Irwin C. Gerson	01/26/2009
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On January 22, 2009, the Reporting Person was granted 28,651 Restricted Stock Units as compensation for serving as an independent director of the Issuer. Each Restricted Stock Unit consists of a right to the issuance of one share of common stock, par value \$.01 ("Common Stock"). The Restricted Stock Units are subject to a two-year vesting period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.	
1 octional persons who are to respond to the concedent of information contained in this form are not required to respond unless the form displays a currently valid ONID illumber.	